Acumen Pharmaceuticals, Inc. 8-K

What Happened
Acumen Pharmaceuticals, Inc. (ABOS) filed an 8-K (Regulation FD disclosure) on January 12, 2026 to post an updated corporate presentation on its investor website. The presentation adds nonclinical murine brain exposure data supporting the company’s Enhanced Brain Delivery (EBD™) program (data presented at CTAD 2025), updates previously shared fluid biomarker views from its Phase 1 INTERCEPT‑AD study, and adds ACU234 to the EBD-related pipeline. A copy of the presentation was attached as Exhibit 99.1 to the filing.

Key Details

• Filing date: January 12, 2026 (Item 7.01 Regulation FD disclosure).
• New content: nonclinical murine brain exposure data presented at CTAD 2025 supporting the EBD™ program.
• Clinical update: updated views of fluid biomarker data from the Phase 1 INTERCEPT‑AD study.
• Pipeline update: inclusion of ACU234 in the pipeline related to the EBD program.
• Presentation posted at: https://investors.acumenpharm.com/news-events/presentations and attached as Exhibit 99.1.

Why It Matters
This filing is a non-financial disclosure intended to share scientific and pipeline updates with investors and the market. The new preclinical brain exposure data and updated biomarker information signal progress in Acumen’s EBD program and formally add ACU234 to that program’s pipeline. The 8-K does not provide financial results, guidance, or clinical outcome details beyond the presentation; investors should review the attached presentation and future filings/releases for quantitative results or clinical milestones.